Effect of CGF on Short Term Clinical Outcomes After Partially Impacted Mandibular Third Molar Surgery
Launched by EGE UNIVERSITY · Apr 11, 2019
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
The study population was composed of subjects presenting to the Department of Oral Surgery for evaluation and management of bilateral, partially-impacted mandibular third molars. The protocol for this study was approved by the local ethics committee and all participants signed an informed consent.
A patient who was referred for extraction of mandibular third molars was examined clinically and radiologically according to the inclusion criteria.
Before the partially-impacted mandibular third molar surgery, randomisation was achieved by use of sealed envelopes, selected by the patient. The e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1- Bilateral, vertically, partially-impacted Class I, Level B third molars
- Exclusion Criteria:
- • 1. Infection of the surgical region
- • 2. Smoking habit
- • 3. Alcohol usage
- • 4. Physical or mental disability
- • 5. Thrombocytopenia
- • 6. Chemotherapy in head and neck region
- • 7. Pregnant woman or woman in menstrual cycle
About Ege University
Ege University, a prestigious institution located in Izmir, Turkey, is renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, Ege University leverages its extensive academic resources and expertise in various healthcare fields to facilitate innovative clinical studies. The university is dedicated to enhancing patient care through rigorous research methodologies and collaboration with multidisciplinary teams, ensuring the development of effective therapies and interventions. With a strong focus on ethical standards and regulatory compliance, Ege University aims to contribute significantly to the global medical community by fostering groundbreaking discoveries and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İzmir, Bornova, Turkey
Patients applied
Trial Officials
Gözde Işık
Principal Investigator
Oral Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials